Valuation: Zai Lab Limited

Market Cap 2.89B 2.52B 2.38B 2.16B 4.04B 277B 4.06B 28.46B 10.98B 141B 10.84B 10.6B 453B P/E 2026 *
-11.6x
P/E 2027 * -11.6x
Enterprise Value 2.43B 2.12B 2B 1.82B 3.4B 233B 3.41B 23.94B 9.24B 118B 9.12B 8.92B 381B EV / Sales 2026 *
5.56x
EV / Sales 2027 * 4.54x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week+7.77%
Current month+1.83%
1 month+0.91%
3 months+39.62%
6 months+37.04%
Current year+50.00%
1 week 20.6
Extreme 20.6
23.2
1 month 20.4
Extreme 20.4
23.4
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
108
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%+7.77%-20.71%-8.26% 2.89B
-0.58%+0.43%+31.09%-4.81% 78.35B
-2.55%+6.99%+505.27%+47.92% 61.52B
-1.11%+5.08%-11.47%-33.91% 59.78B
+0.14%-1.20%-11.64%+24.21% 46.53B
-0.24%+1.22%+2.26%+151.03% 45.5B
-1.62%-0.76%+49.85%-14.92% 31.84B
-1.81%+3.16%+45.71%+110.57% 25.4B
+0.47%+3.26%-0.77%+142.41% 21.43B
+0.27%+1.96%+62.19%+102.81% 15.77B
Average -0.78%+2.20%+65.18%+51.70% 42.9B
Weighted average by Cap. -0.92%+2.35%+92.67%+39.91%

Financials

2026 *2027 *
Net sales 436M 381M 359M 326M 611M 41.88B 614M 4.3B 1.66B 21.29B 1.64B 1.6B 68.51B 552M 481M 455M 413M 773M 52.98B 777M 5.45B 2.1B 26.94B 2.07B 2.03B 86.67B
Net income -241M -210M -198M -180M -337M -23.09B -339M -2.37B -916M -11.74B -904M -884M -37.78B -211M -184M -174M -158M -296M -20.25B -297M -2.08B -803M -10.3B -793M -775M -33.13B
Net Debt -458M -399M -377M -342M -641M -43.91B -644M -4.51B -1.74B -22.33B -1.72B -1.68B -71.84B -381M -332M -314M -285M -533M -36.54B -536M -3.76B -1.45B -18.58B -1.43B -1.4B -59.78B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
18/09/26 €22.20 -0.89%
17/09/26 €22.40 +4.67%
16/09/26 €21.40 0.00%
15/09/26 €21.40 +0.94%
14/09/26 €21.20 +2.91%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
25.70USD
Average target price
33.14USD
Spread / Average Target
+28.95%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!